StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CADLBullishAnalyst Target Updateanalyst
Medium materiality6/10

Jefferies initiates Candel Therapeutics at Buy with $25 target

Oct 22, 2026, 6:25 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Bullish analyst view, though the signal is based on a single analyst opinion and the target is not a forecast guarantee.

AI summary

What happened, with direct paths to the underlying reporting

Jefferies initiated coverage of CADL with a Buy rating and a $25 target versus the posted price of $8.37, indicating substantial analyst-implied upside.

  • Jefferies initiated CADL at Buy.
  • Target: $25; posted price: $8.37.

Key facts

  1. 01

    Target: $25

  2. 02

    Posted price: $8.37

  3. 03

    Analyst firm: Jefferies

  4. 04

    Analyst: Maury Raycroft

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.